Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System

Author:

Choi Jung Yoon1,Lee Yongjoon2,Park Nam Gi1,Kim Mi Sung1,Rhie Sandy Jeong1ORCID

Affiliation:

1. Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea

2. Conpapa Inc., Seoul 06164, Republic of Korea

Abstract

We aimed to analyze the characteristics of serious adverse events following immunizations (AEFIs) to identify potential safety information and prediction features. We screened the individual case safety reports (ICSRs) in adults who received mRNA-based COVID-19 vaccines using the Vaccine Adverse Event Reporting System until December 2021. We identified the demographic and clinical characteristics of ICSRs and performed signal detection. We developed prediction models for serious AEFIs and identified the prognostic features using logistic regression. Serious ICSRs and serious AEFIs were 51,498 and 271,444, respectively. Hypertension was the most common comorbidity (22%). Signal detection indicated that the reporting odds ratio of acute myocardial infarction (AMI) was more than 10 times. Those who had experienced myocardial infarction (MI) were 5.7 times more likely to suffer from MI as an AEFI (95% CI 5.28–6.71). Moreover, patients who had atrial fibrillation (AF), acute kidney injury (AKI), cardiovascular accident (CVA), or pulmonary embolism (PE) were 7.02 times, 39.09 times, 6.03 times, or 3.97 times more likely to suffer from each AEFI, respectively. Our study suggests that vaccine recipients who had experienced MI, AF, AKI, CVA, or PE could require further evaluation and careful monitoring to prevent those serious AEFIs.

Funder

Korean Government Ministry of Science

Publisher

MDPI AG

Reference42 articles.

1. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia;Li;N. Engl. J. Med.,2020

2. Nanocarrier vaccines for SARS-CoV-2;Machhi;Adv. Drug Deliv. Rev.,2021

3. WHO (2023, April 09). Serious AEFI. Available online: https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/aefi/serious-aefi.

4. SARS-CoV-2 vaccines: Status report;Amanat;Immunity,2020

5. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine;Polack;N. Engl. J. Med.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3